Chemistry lab vials and beakers

Scientific innovation is our passion

Peptide-formulated neuromodulator, developed and manufactured exclusively by Revance. An illustration of our peptide-formulated neuromodulator.
Developed and manufactured exclusively by Revance.

At Revance, every product we develop is driven by scientific ingenuity

It’s our passion to pioneer novel technologies across aesthetics, skincare, and therapeutics. To be successful, we pursue the latest scientific breakthroughs and find inventive ways to implement them. Through our Innovation Programs, we actively engage scientists to help us rethink our product development.

Taking medical device technology to the next level

Biomedical innovation focuses on the research and development of medical devices for various patient benefits. Medical device development requires significant evaluation of concepts, prototypes, and knowledge generation to help optimize patient outcomes. These processes are led by medical, biological, and engineering sciences that incorporate a wide range of technologies to address provider and patient needs.

Enhancing formulations with cutting-edge ingredients

Formulation Sciences focus on the precise selection and integration of chemical ingredients to create innovative skin products. To determine what formulation helps benefit the skin, this process involves careful research, design, selection, mixing, packaging, and testing. This ensures we meet established criteria for sensory attributes, skin effectiveness, stability, and safety. Revance’s chemists and scientists, many with advanced degrees, play a crucial role in bringing novel products to market.

Chemist in a lab, working with a test tube

R&D

We have decades of experience in the research and development of pharmaceutical semi-solids, liquids and gels. In conjunction with our cGMP-compliant manufacturing capabilities and research expertise, we proudly provide the following solutions:

  • Formulation for lab scale, feasibility studies, registration batches, and scale up for commercialization
  • Technical transfer and process validation
  • Manufacturing and packaging of clinical trial supply
  • Raw material testing
  • Bulk uniformity and hold-time testing
  • Clinical trials supplies testing
  • ICH stability testing

Clinical Studies

At Revance, developing safe and effective products is our highest priority and we strive to conduct the highest quality clinical research. If you are interested in being an investigator in a Revance-sponsored clinical trial, please provide your information by clicking on the link below.

Clinical Trial Investigator

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION


Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:
Glabellar lines (≥1%): headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

Instagram LinkedIn

©2025 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by REVANCE. All other trademarks are the property of their respective owners. CORP-00147

CALIFORNIA PRIVACY POLICYCALIFORNIA COMPLIANCE DECLARATIONPRIVACY POLICYTERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.